Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS20026621HPVENSG00000136997.22protein_codingMYCYesNo4609P01106
TVIS20026372HPVENSG00000136997.22protein_codingMYCYesNo4609P01106
TVIS20026373HPVENSG00000136997.22protein_codingMYCYesNo4609P01106
TVIS20016670HPVENSG00000136997.22protein_codingMYCYesNo4609P01106
TVIS20026374HPVENSG00000136997.22protein_codingMYCYesNo4609P01106
TVIS20016846HPVENSG00000136997.22protein_codingMYCYesNo4609P01106
TVIS20026375HPVENSG00000136997.22protein_codingMYCYesNo4609P01106
TVIS20026376HPVENSG00000136997.22protein_codingMYCYesNo4609P01106
TVIS20026625HPVENSG00000136997.22protein_codingMYCYesNo4609P01106
TVIS20024113HPVENSG00000136997.22protein_codingMYCYesNo4609P01106
TCGA Plot Options
Drug Information
GeneMYC
DrugBank IDDB08813
Drug NameNadroparin
Target IDBE0004689
UniProt IDP01106
Regulation Typeinhibitor
PubMed IDs19757196; 19261492
CitationsNagy Z, Turcsik V, Blasko G: The effect of LMWH (Nadroparin) on tumor progression. Pathol Oncol Res. 2009 Dec;15(4):689-92. doi: 10.1007/s12253-009-9204-7.@@Sustar V, Jansa R, Frank M, Hagerstrand H, Krzan M, Iglic A, Kralj-Iglic V: Suppression of membrane microvesiculation--a possible anticoagulant and anti-tumor progression effect of heparin. Blood Cells Mol Dis. 2009 May-Jun;42(3):223-7. doi: 10.1016/j.bcmd.2009.01.012. Epub 2009 Mar 3.
GroupsApproved; Investigational
Direct Classification
SMILES
Pathways
PharmGKB
ChEMBL